Showing results (21-30 of 128) with videos related to

Sort By:
Pageof 13
Muscle & Nerve|December 23, 2025
Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral SclerosisAngela Genge, Jeffrey Rothstein, Shari De Silva, et al.
AJNR. American Journal of Neuroradiology|March 15, 2003
Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopySanjay Kalra, Neil R Cashman, Zografos Caramanos, et al.
Muscle & Nerve|June 9, 2025
Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of TreatmentAngela Genge, Gary L Pattee, Gen Sobue, et al.
Magnetic Resonance Imaging|November 7, 2016
Hair product artifact in magnetic resonance imagingSneha Chenji, Alan H Wilman, Dennell Mah, et al.
Dysphagia|May 5, 2018
A Preliminary Videofluoroscopic Investigation of Swallowing Physiology and Function in Individuals with Oculopharyngeal Muscular Dystrophy (OPMD)Ashley A Waito, Catriona M Steele, Melanie Peladeau-Pigeon, et al.
Clinical Pharmacology in Drug Development|September 28, 2022
Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral FilmJames Wymer, Stephen Apple, Antoinette Harrison, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 20, 2023
Harmonized standard operating procedures for administering the ALS functional rating scale-revisedJeremy M Shefner, Tommy Bunte, Gale Kittle, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|April 8, 2015
Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio SyndromeMarta Kaminska, Franceen Browman, Daria A Trojan, et al.
Muscle & Nerve|February 7, 2026
Generalizability of Edaravone EfficacyBenjamin Rix Brooks, David L Ennist, Danielle Beaulieu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 7, 2026
Cell free miRNAs are pharmacodynamic biomarkers for enhanced Dicer activity by Enoxacin in human patients with Amyotrophic lateral sclerosisIddo Magen, Hannah Marlene Kaneb, Maria Masnata, et al.
Pageof 13